DRAXIS to Report Third Quarter Results on November 1st
23 Octubre 2007 - 7:30AM
PR Newswire (US)
MISSISSAUGA, ON, Oct. 23 /PRNewswire-FirstCall/ -- DRAXIS Health
Inc. (TSX: DAX) (NASDAQ:DRAX) will report financial and operating
results for its Third Quarter 2007 on Thursday November 1, 2007.
Senior management will host a conference call and live audio
webcast at 10:00 a.m. ET to discuss the results and recent
activities. Details of the conference call and webcast are as
follows: Date / time Thursday November 1, 2007 at 10:00 a.m. (ET)
-------------------------------------------------------------------------
Dial-in number 1 (800) 819-9193 ACCESS CODE 4571610 and access code
-------------------------------------------------------------------------
Audio webcast Access the live call on the DRAXIS web site at
http://www.draxis.com/. The call will be archived on the web site
for 30 days.
-------------------------------------------------------------------------
Audio Player You will require the Windows Media Player,
downloadable free from
http://www.microsoft.com/windows/windowsmedia/download
/default.asp.
-------------------------------------------------------------------------
Playback An audio playback of the call will be available until
midnight November 8, 2007. To listen, dial 1 (888) 203-1112 and
refer to access code 4571610.
-------------------------------------------------------------------------
About DRAXIS Health Inc.: DRAXIS Health, through its wholly owned
operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc.,
provides products in three categories: sterile products,
non-sterile products and radiopharmaceuticals. Sterile products
include liquid and freeze-dried (lyophilized) injectables plus
sterile ointments and creams. Non-sterile products are produced as
solid oral and semi-solid dosage forms. Radiopharmaceuticals are
used for both therapeutic and diagnostic molecular imaging
applications. Pharmaceutical contract manufacturing services are
provided through the DRAXIS Pharma division and
radiopharmaceuticals are developed, produced, and sold through the
DRAXIMAGE division. DRAXIS employs approximately 500 staff in its
Montreal facility. For additional information please visit
http://www.draxis.com/ Caution Concerning Forward-Looking
Statements This news release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and as
contemplated under other applicable securities legislation. These
statements can be identified by the use of forward-looking
terminology such as "may," "will," "expect," "anticipate,"
"estimate," "continue," "plan," "intend," "believe" or other
similar words. These statements discuss future expectations
concerning results of operations or financial condition or provide
other forward-looking information. Our actual results, performance
or achievements could be significantly different from the results
expressed in, or implied by, those forward-looking statements. You
should not place undue reliance on any forward-looking statement,
which speaks only as of the date made. These statements are not
guarantees of future performance. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks,
uncertainties and other factors that may cause the actual results
or performance of the Company to be materially different from such
statements or from any future results or performance implied
thereby. Factors that could cause the Company's results or
performance to differ materially from a conclusion, forecast or
projection in the forward-looking statements include, but are not
limited to: - the achievement of desired clinical trial results
related to the Company's pipeline products; - timely regulatory
approval of the Company's products; - the ability to comply with
regulatory requirements applicable to the manufacture and marketing
of the Company's products; - the Company's ability to obtain and
enforce effective patents; - the non-infringement of third party
patents or proprietary rights by the Company and its products; -
factors beyond our control that could cause interruptions in our
operations in our single manufacturing facility (including, without
limitation, material equipment breakdowns); - reimbursement
policies related to health care; - the establishment and
maintenance of strategic collaborative and commercial
relationships; - the Company's dependence on a small number of key
customers; - the disclosure of confidential information by our
collaborators, employees or consultants; - the preservation of
healthy working relationships with the Company's union and
employees; - the Company's ability to grow the business; - the
fluctuation of our financial results and exchange and interest rate
fluctuations; - the adaptation to changing technologies; - the loss
of key personnel; - the avoidance of product liability claims; -
the loss incurred if current lawsuits against us succeed; - the
volatility of the price of our common shares; - market acceptance
of the Company's products; and - the risks described in "Item 3.
Key Information - Risk Factors" in the Annual Report Form 20-F
filed by the Company with the United States Securities and Exchange
Commission and which is also filed as the Company's Annual
Information Form with Canadian securities regulators. For
additional information with respect to certain of these and other
factors, and relating to the Company generally, reference is made
to the Company's most recent filings with the United States
Securities and Exchange Commission (available on EDGAR at
http://www.sec.gov/) and the filings made by the Company with
Canadian securities regulators (available on SEDAR at
http://www.sedar.com/). The forward-looking statements contained in
this new release represent the Company's expectations as at October
22, 2007. Unless otherwise required by applicable securities laws,
the Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: DRAXIS Health
Inc. CONTACT: DRAXIS Health Inc.: Jerry Ormiston, Executive
Director, Investor Relations, Phone: 1-877-441-1984
Copyright
Draxis Health (MM) (NASDAQ:DRAX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Draxis Health (MM) (NASDAQ:DRAX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Draxis Health (MM) (NASDAQ): 0 recent articles
Más de Draxis Health Inc. - Common Shares (MM) Artículos de Noticias